TEGISON
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Sep 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEGISON is an oral small-molecule capsule approved by the FDA in 1986 for an unknown indication under Roche's sponsorship. The mechanism of action and pharmacologic class are not specified in available data. The product is currently approaching loss of exclusivity.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a mature team focused on optimization and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TEGISON currently shows zero linked job openings, reflecting its mature LOE status and limited active hiring. Working on this product offers exposure to late-lifecycle commercial strategy, cost-containment initiatives, and transition planning—valuable for career development in pharma operations and portfolio management.
Brand ManagerSenior Sales Representative
Worked on TEGISON at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.